Pacific Edge Limited has released a shareholder letter for October 2025. The letter addresses the current status of Medicare reimbursement for Cxbladder, noting recent developments including Novitas' announcement to convene a Contractor Advisory Committee to review evidence related to urine-based biomarkers. The letter also covers test volume trends for the second quarter of the 2026 financial year, the impact of administrative changes in the United States, and the completion of a capital raise totaling $20.71 million. The company intends to report first half 2026 financial results in late November. The full letter can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacific Edge Limited published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.